Sinopharm Group Co. Ltd (X2S) - Total Liabilities

Latest as of December 2025: €256.20 Billion EUR ≈ $299.53 Billion USD

Based on the latest financial reports, Sinopharm Group Co. Ltd (X2S) has total liabilities worth €256.20 Billion EUR (≈ $299.53 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Sinopharm Group Co. Ltd - Total Liabilities Trend (2013–2025)

This chart illustrates how Sinopharm Group Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. See X2S working capital efficiency to evaluate short-term liquidity relative to the company's equity base.

Sinopharm Group Co. Ltd Competitors by Total Liabilities

The table below lists competitors of Sinopharm Group Co. Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Inesa Intelligent Tech Inc A SHG:600602	China	CN¥2.89 Billion
NH Hoteles MC:NHH	Spain	€3.32 Billion
TIME Dotcom Bhd KLSE:5031	Malaysia	RM1.13 Billion
Mirae Asset Life Insurance Co Ltd KO:085620	Korea	₩30.73 Trillion
PNB Housing Finance Limited NSE:PNBHOUSING	India	Rs677.86 Billion
Veracyte Inc NASDAQ:VCYT	USA	$110.12 Million
Air China Limited F:AD2	Germany	€303.82 Billion
Eclat Textile Co Ltd TW:1476	Taiwan	NT$5.60 Billion

Liability Composition Analysis (2013–2025)

This chart breaks down Sinopharm Group Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Sinopharm Group Co. Ltd market cap and net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.41	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	3.05	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.66	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Sinopharm Group Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Sinopharm Group Co. Ltd (2013–2025)

The table below shows the annual total liabilities of Sinopharm Group Co. Ltd from 2013 to 2025.

Year	Total Liabilities	Change
2025-12-31	€256.20 Billion ≈ $299.53 Billion	-3.74%
2024-12-31	€266.14 Billion ≈ $311.15 Billion	+1.17%
2023-12-31	€263.08 Billion ≈ $307.56 Billion	+3.29%
2022-12-31	€254.71 Billion ≈ $297.78 Billion	+8.04%
2021-12-31	€235.76 Billion ≈ $275.63 Billion	+6.54%
2020-12-31	€221.29 Billion ≈ $258.71 Billion	+14.69%
2019-12-31	€192.95 Billion ≈ $225.58 Billion	+15.20%
2018-12-31	€167.50 Billion ≈ $195.82 Billion	+41.62%
2017-12-31	€118.27 Billion ≈ $138.27 Billion	+4.50%
2016-12-31	€113.18 Billion ≈ $132.32 Billion	+14.84%
2015-12-31	€98.55 Billion ≈ $115.22 Billion	+6.70%
2014-12-31	€92.37 Billion ≈ $107.99 Billion	+20.20%
2013-12-31	€76.84 Billion ≈ $89.84 Billion	--

About Sinopharm Group Co. Ltd

F:X2S Germany Medical Distribution

Market Cap

$2.83 Billion

€2.42 Billion EUR

Market Cap Rank

#5200 Global

#835 in Germany

Share Price

€1.80

Change (1 day)

-1.88%

52-Week Range

€1.80 - €2.37

All Time High

€2.71